Navigation Links
deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
Date:10/11/2007

REYKJAVIK, Iceland, Oct. 11 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN) today announced the launch of deCODE MI(TM), a reference laboratory test for variations in the genome (called SNPs) that the company has associated with increased risk of myocardial infarction, or heart attack. The SNPs are located on chromosome 9 and were discovered by deCODE earlier this year. As described in the journal Science in July, deCODE scientists found that people who carry two copies of these variants are at double the risk of suffering an early heart attack -- before the age of 50 in men and 60 in women -- than are those who do not carry them. deCODE validated the role of these variants in five groups of patients and controls from Iceland and the United States, and other researchers have replicated this finding in several European, US, and Canadian cohorts.

"With the launch of deCODE MI, we have taken another of our breakthroughs in genetics and transformed it into a new tool in the fight to prevent heart attack. While many risk factors for heart attack are understood, the disease remains the leading cause of death in the industrialized world and the early- onset cases often take both patients and doctors so dangerously by surprise. deCODE MI(TM) tests for a genetic risk factor that is independent of other risks such as cholesterol, obesity and smoking, and therefore provides a means of identifying individuals who may derive particular benefit from earlier and more aggressive prevention efforts," said Dr. Kari Stefansson, CEO of deCODE.

How to order deCODE MI(TM)

deCODE MI(TM) is performed in deCODE's Clinical Laboratory Improvement Amendments (CLIA) certified laboratory, and must be authorized by a qualified physician. If you are an individual who would like more information on deCODE MI(TM) to discuss with your doctor, or a physician interested in learning more about deCODE MI(TM) for your patients, please visit us at http://www.decodediagnostics.com.

The variants detected by deCODE MI(TM), are two SNPs (single-letter variants in the genome) on chromosome 9p21. They were discovered by deCODE scientists earlier this year through genome-wide SNP analysis in Iceland and replicated in three cohorts of European descent from Philadelphia, Atlanta and Durham, North Carolina. Of the 17,000 patients and control subjects in the study, more than 20% of participants carried two copies of the variant, corresponding to a more than 60% increase in risk of heart attack, regardless of age of onset, compared to those without the variant. In early-onset cases -- men and women who suffered a heart attack before the ages of 50 and 60, respectively -- carrying two copies of the variant corresponds to an approximate doubling of risk compared to non-carriers. The variant is estimated to account for approximately one-fifth of the incidence of heart attack in populations of European origin, and nearly one third of early-onset cases, making it the one of the most significant genetic risk factors found to date for heart attack as a public health problem.

About deCODE

deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of drugs and diagnostics for common diseases. deCODE is a global leader in gene discovery -- our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease. Through its CLIA-certified laboratory, deCODE is offering a growing range of DNA-based tests for gauging risk and empowering prevention of common diseases, including deCODE T2(TM) in type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; and deCODE MI(TM) for heart attack. deCODE is delivering on the promise of the new genetics(SM). On the web at http://www.decode.com.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties include, among others, those relating to technology and product development, integration of acquired businesses, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

Contact:

deCODE genetics

Berglind Olafsdottir Edward Farmer Joy Bessenger

+354 664 2393 +1 212 343 2819 +1 212 481 3891

bro@decode.is edward.farmer@decode.is ir@decode.is


'/>"/>
SOURCE deCODE genetics
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
2. deCODE Announces Positive Topline Results for Phase I Study of DG051 for the Prevention of Heart Attack
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
5. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
6. Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo
7. Six-Week Investigational Study In Adults With Major Depressive Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole Therapy With Antidepressants
8. Major Manufacturer of Unapproved and Adulterated Drugs
9. Exforge Helps Vast Majority of Patients Effectively Control Their Blood Pressure After Failing on Other Medicines, According to New Clinical Data
10. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
11. Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/8/2017)... 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... its financial results for the second quarter ended June ... second quarter 2017 and to date: ... programs for the Company,s lead project, BL-8040: ... with BL-8040 as novel stem cell mobilization treatment for ...
(Date:8/7/2017)... (NYSE: DPLO), the nation,s largest independent specialty pharmacy, announced financial ... unless otherwise noted, are to the quarter ended June 30, ... 2017 Highlights include: Revenue of $1,126 ... Total prescriptions dispensed of 220,000, compared to 241,000 ... Gross profit per prescription dispensed of $371, ...
(Date:8/2/2017)... , Aug. 2, 2017 ... Who,s Who as a Pinnacle Lifetime Professional in ... Key Account Manager at Turing Pharmaceuticals, AG. Her ... troubleshooting and relationship building.                ... more than 25 years of experience as a ...
Breaking Medicine Technology:
(Date:8/19/2017)... ... August 19, 2017 , ... Parker at Stonegate, an assisted ... passionate employees, caregivers, volunteers, thought leaders, researchers, educators and partners leading the way ... time to refresh the carpeting with the goal of maintaining the same precise ...
(Date:8/18/2017)... ... ... More than 20,000 pairs of shoes made their way across the Atlantic this ... conjoined the passions of an NBA star, a Liberty University student, and an LU ... save lives from the rampant infections transmitted through the soil. , AMERICAN SOLES , ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... of “Vision & Hearing,” advocating for active, healthy lifestyles and highlighting the importance ... for individuals with hearing impairments and shares the latest innovations in hearing aid ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... services and financial consultations to communities throughout the greater DC region, is inaugurating ... the goal of rescuing local animals and training them to be companions for ...
(Date:8/18/2017)... John, IN (PRWEB) , ... August 18, 2017 , ... ... to communities in northwest Indiana, is campaigning in support of Campagna Academy in a ... referred to as the “Hoosier Boys’ Town of Indiana,” Campagna Academy is a nonprofit ...
Breaking Medicine News(10 mins):